Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads

NCT ID: NCT02290028

Last Updated: 2021-03-24

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

2226 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-12-16

Study Completion Date

2020-01-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The QP ExCELs study is designed to confirm safety and efficacy of the BIOTRONIK Sentus OTW QP left ventricular leads to satisfy FDA requirements for regulatory approval of the leads in the US. The Sentus OTW QP leads received FDA approval on May 4, 2017.

Long-term safety of the BIOTRONIK Sentus OTW QP left ventricular leads will be confirmed during the ongoing post approval phase (US sites only).

A protocol update was implemented on September 6, 2019 to transition the long-term follow up for the ongoing Sentus QP Study to a new EP PASSION real-world data methodology.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sentus QP left ventricular lead

Subjects consented and implanted with a Sentus QP left ventricular lead.

Group Type OTHER

Sentus QP left ventricular lead

Intervention Type DEVICE

Implantation of quadripolar left ventricular lead in patients with CRT-D indication

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sentus QP left ventricular lead

Implantation of quadripolar left ventricular lead in patients with CRT-D indication

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sentus OTW QP L Sentus OTW QP S Sentus OTW QP S-xx/49 Sentus OTW QP L-xx/49

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Standard CRT-D indication according to clinical routine
* De novo implantation or upgrade from existing ICD or pacemaker implant utilizing a BIOTRONIK CRT-D system with IS4 LV port and Sentus QP LV lead
* Patient is able to understand the nature of the clinical investigation and provide written informed consent
* Patient is able and willing to complete all routine study visits at the investigational site through 5 years of follow-up
* Patient accepts Home Monitoring® concept
* Age ≥ 18 years

Exclusion Criteria

* Chronic atrial fibrillation
* Contraindication to CRT-D therapy
* Currently implanted with an endocardial or epicardial left ventricular lead or had prior attempt to place a left ventricular lead
* Cardiac surgical procedure, such as coronary artery bypass graft or valve surgery that is planned to occur within 6 months after implant or ablation that is planned to occur within 90 days after implant (ablations planned to occur prior to or at implant are not exclusionary)
* Expected to receive a heart transplant or ventricular assist device within 6 months
* Life expectancy less than 12 months
* Participation in any other investigational cardiac clinical investigation during the course of the study
* Presence of another life-threatening, underlying illness separate from their cardiac disorder
* Pregnant or breast-feeding at time of enrollment
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biotronik, Inc.

INDUSTRY

Sponsor Role collaborator

Biotronik SE & Co. KG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Antonio Curnis, Prof.

Role: STUDY_CHAIR

Spedali Civili - Universita di Brescia, Italy

Mattias Roser, Dr.

Role: STUDY_CHAIR

Charité CBF Berlin, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fairhope, Alabama, United States

Site Status

Anchorage, Alaska, United States

Site Status

Chula Vista, California, United States

Site Status

Inglewood, California, United States

Site Status

Rancho Mirage, California, United States

Site Status

Aurora, Colorado, United States

Site Status

Washington D.C., District of Columbia, United States

Site Status

Orlando, Florida, United States

Site Status

Orlando, Florida, United States

Site Status

Pensacola, Florida, United States

Site Status

Tampa, Florida, United States

Site Status

Atlanta, Georgia, United States

Site Status

Chicago, Illinois, United States

Site Status

Joliet, Illinois, United States

Site Status

Fort Wayne, Indiana, United States

Site Status

Iowa City, Iowa, United States

Site Status

Kansas City, Kansas, United States

Site Status

Lexington, Kentucky, United States

Site Status

Lexington, Kentucky, United States

Site Status

New Orleans, Louisiana, United States

Site Status

Bangor, Maine, United States

Site Status

Boston, Massachusetts, United States

Site Status

Burlington, Massachusetts, United States

Site Status

Fall River, Massachusetts, United States

Site Status

Worcester, Massachusetts, United States

Site Status

Ann Arbor, Michigan, United States

Site Status

Detroit, Michigan, United States

Site Status

Ypsilanti, Michigan, United States

Site Status

Tupelo, Mississippi, United States

Site Status

Kansas City, Missouri, United States

Site Status

Saint Charles, Missouri, United States

Site Status

Springfield, Missouri, United States

Site Status

St Louis, Missouri, United States

Site Status

St Louis, Missouri, United States

Site Status

Kalispell, Montana, United States

Site Status

Browns Mills, New Jersey, United States

Site Status

Englewood, New Jersey, United States

Site Status

Hackensack, New Jersey, United States

Site Status

Neptune City, New Jersey, United States

Site Status

Brooklyn, New York, United States

Site Status

Flushing, New York, United States

Site Status

New York, New York, United States

Site Status

New York, New York, United States

Site Status

New York, New York, United States

Site Status

New York, New York, United States

Site Status

The Bronx, New York, United States

Site Status

Valhalla, New York, United States

Site Status

Asheville, North Carolina, United States

Site Status

Chapel Hill, North Carolina, United States

Site Status

Greensboro, North Carolina, United States

Site Status

Greenville, North Carolina, United States

Site Status

Winston-Salem, North Carolina, United States

Site Status

Winston-Salem, North Carolina, United States

Site Status

Fargo, North Dakota, United States

Site Status

Cincinnati, Ohio, United States

Site Status

Columbus, Ohio, United States

Site Status

Columbus, Ohio, United States

Site Status

Toledo, Ohio, United States

Site Status

Bryn Mawr, Pennsylvania, United States

Site Status

Philadelphia, Pennsylvania, United States

Site Status

Wynnewood, Pennsylvania, United States

Site Status

Warwick, Rhode Island, United States

Site Status

Anderson, South Carolina, United States

Site Status

Columbia, South Carolina, United States

Site Status

Greenville, South Carolina, United States

Site Status

Chattanooga, Tennessee, United States

Site Status

Amarillo, Texas, United States

Site Status

Fort Worth, Texas, United States

Site Status

San Antonio, Texas, United States

Site Status

The Woodlands, Texas, United States

Site Status

Salt Lake City, Utah, United States

Site Status

Burlington, Vermont, United States

Site Status

Norfolk, Virginia, United States

Site Status

Milwaukee, Wisconsin, United States

Site Status

Cheyenne, Wyoming, United States

Site Status

Flinders Medical Center

Bedford Park, , Australia

Site Status

Lyell McEwing Hospital

Elizabeth Vale, , Australia

Site Status

The Northern Hospital

Epping, , Australia

Site Status

Royal Hobart Hospital

Hobart, , Australia

Site Status

Nambour General Hospital

Nambour, , Australia

Site Status

AKH Linz

Linz, , Austria

Site Status

AKH Wien

Vienna, , Austria

Site Status

Klinikum Wels-Grieskirchen GmbH

Wels, , Austria

Site Status

Gentofte Hospital

Hellerup, , Denmark

Site Status

Odense Universitets Hospital

Odense, , Denmark

Site Status

DHZ Berlin

Berlin, , Germany

Site Status

Maria Heimsuchung Caritas Klinik Pankow

Berlin, , Germany

Site Status

Virchow Klinikum

Berlin, , Germany

Site Status

Immanuel Klinikum Herzzentrum Bernau

Bernau, , Germany

Site Status

Städtisches Krankenhaus Bielefeld Mitte

Bielefeld, , Germany

Site Status

Augusta-Kranken-Anstalt Bochum

Bochum, , Germany

Site Status

Augusta Krankenhaus Düsseldorf

Düsseldorf, , Germany

Site Status

Heinrich Heine University Düsseldorf

Düsseldorf, , Germany

Site Status

Universitätsklinik Erlangen

Erlangen, , Germany

Site Status

Elisabeth Krankenhaus Essen

Essen, , Germany

Site Status

UHZ Freiburg

Freiburg im Breisgau, , Germany

Site Status

SRH Wald-Klinikum Gera gGmbH

Gera, , Germany

Site Status

Westpfalzklinikum

Kaiserslautern, , Germany

Site Status

Städtisches Klinikum St. Georg

Leipzig, , Germany

Site Status

UKSH Campus Lübeck

Lübeck, , Germany

Site Status

Marienhospital Lünen

Lünen, , Germany

Site Status

Elbekliniken Stade - Buxtehude

Stade, , Germany

Site Status

SBK Villingen Schwenningen

Villingen, , Germany

Site Status

SHG-Kliniken Völklingen

Völklingen, , Germany

Site Status

Universitätsklinikum Würzburg

Würzburg, , Germany

Site Status

HBK Zwickau

Zwickau, , Germany

Site Status

Semmelweis University

Budapest, , Hungary

Site Status

Barzilai Medical Center

Ashkelon, , Israel

Site Status

Soroka Medical Center

Beersheba, , Israel

Site Status

Rambam Medical Center

Haifa, , Israel

Site Status

Hadassah Medical Center

Jerusalem, , Israel

Site Status

Spedali Civili di Brescia

Brescia, , Italy

Site Status

Azienda Ospedaliero Sant'Anna Como

Como, , Italy

Site Status

Nusch

Bratislava, , Slovakia

Site Status

Vusch East Slovak Cardiology Institute

Košice, , Slovakia

Site Status

Hospital Clinic Provincial de Barcelona

Barcelona, , Spain

Site Status

Hospital Ramón y Cajal Madrid

Madrid, , Spain

Site Status

Kantonspital Luzern

Lucerne, , Switzerland

Site Status

University Hospital Zürich

Zurich, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Denmark Germany Hungary Israel Italy Slovakia Spain Switzerland

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CR016

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Biventricular Tachycardias Outcome Trial
NCT00729235 COMPLETED PHASE4